ACADIA Pharmaceuticals Inc. (ACAD) Stock

ACADIA Pharmaceuticals Inc. (ACAD) is a Healthcare stock trading at $29.50 (as of 2026-08-21), with a market capitalization of $5.05B and a trailing P/E of 13.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ACADIA Pharmaceuticals Inc. develops and commercializes small-molecule therapies for central nervous system disorders. It markets NUPLAZID (pimavanserin) for hallucinations and delusions linked to Parkinson’s disease psychosis and has product candidates in clinical development for conditions including Alzheimer’s disease psychosis, Rett syndrome, and schizophrenia.

Understand ACADIA Pharmaceuticals Inc.: how it makes money

ACADIA develops and commercializes small-molecule medicines for central nervous system disorders, making money by selling approved treatments such as NUPLAZID.

ACADIA's drug-sales model produces very high gross margins, but its operating costs still exceed gross profit, with gross margin 91% and operating margin -2%.

Business quality (Weak): Weak: gross margin 91% is strong, but operating margin -2% shows the company is not yet converting sales into operating profit.

Valuation: At 13× earnings, ACAD trades 22% below the Pharmaceutical Products average (17×).

Bull case

  • Sales growth can improve scale: Quarterly revenue $300M (+10% YoY) shows the commercial base is growing, which could improve operating leverage if that pace continues.
  • Lower valuation leaves room: P/E 13.4× vs Pharmaceutical Products industry 17× (22% below) gives investors a lower starting valuation than industry peers, which could support upside if execution improves.

Bear case

  • Sales have not produced profit: Operating margin -2% means strong product gross economics have not yet translated into positive operating earnings, leaving durable profitability unproven.
  • One product drives most sales: Non-GAAP Adjusted NUPLAZID Net Sales $170M = 57% of revenue shows that more than half of sales depends on one product, so a setback for NUPLAZID could materially reduce revenue.
Valuation — source: SEC EDGAR (first-party)
Price$29.50
Market Cap$5.05B
P/E Ratio13.4
EV / EBITDA58.3
Price / Book4.05
Price / Sales4.61
FCF Yield2.3%
DCF Value (model)$3.77
DCF Upside vs Price-87.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.07B
Net Margin36.5%
Revenue Growth (YoY)9.7%
EPS Growth (YoY)-81.8%
FCF Growth (YoY)41.6%
Financial Health — source: SEC EDGAR
Altman Z-Score8.85 (safe)
Valuation vs Sector & Industry
Stock P/E13.4
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector-38.1%
vs Industry-21.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBAKER BROS. ADVISORS LP ($954.88M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCatherine E. Owen Adams
Employees653
CountryUS
IPO Date2005-03-18

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Prestige Consumer Healthcare Inc. (PBH)
  • Lakefront Biotherapeutics NV (LKFT)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Indivior Pharmaceuticals Inc (INDV)
  • Harmony Biosciences Holdings, Inc. (HRMY)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Collegium Pharmaceutical, Inc. (COLL)
ACAD earnings history · ACAD institutional & insider holders · ACAD KPIs & operating metrics · ACAD financials · ACAD investor presentations & press releases · ACAD SEC filings · ACAD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.